Wyeth Extends Agreement with Affymetrix to 15 Years
Affymetrix Inc. announced that Wyeth has signed another agreement with Affymetrix to use GeneChip(R) microarray technology for three more years, further extending the relationship that began in 1994. Under the agreement, Wyeth will continue to apply Affymetrix technology in numerous areas of the drug discovery and development process. The company will continue to use Affymetrix microarray technology to identify new drug targets and gain a better understanding of the genetic markers that potentially correlate with a patient's response to therapy.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
New clinical study aims to prevent type 1 diabetes in children
First genetic link to common migraine exposed - Genetic variant may increase susceptibility to migraine triggers
Affibody and Agilent Technologies to Develop Robust Protein Sample
UCB and Proteros expand successful protein x-ray crystallography collaboration - Collaboration aims to accelerate drug discovery for new therapies in central nervous system (CNS) disorders and immunology diseases

Biological risk potential of nanoparticles studied
Irukandji_syndrome
